Cite
HARVARD Citation
Shima, M. et al. (2021). Long‐term safety and efficacy of emicizumab for up to 5.8 years and patients' perceptions of symptoms and daily life: A phase 1/2 study in patients with severe haemophilia A. Haemophilia. 27 (1), pp. 81-89. [Online].